Drug Action
Basiliximab is a monoclonal antibody that acts as an interleukin-2 receptor antagonist and prevents T-lymphocyte proliferation.
PDF page 911
Loading InternPractice…
Drug reference
Basiliximab is a monoclonal antibody that acts as an interleukin-2 receptor antagonist and prevents T-lymphocyte proliferation.
PDF page 911
Prophylaxis of acute rejection in allogeneic renal transplantation used in combination with ciclosporin and corticosteroid-containing immunosuppression regimens (specialist use only) ▶BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION ▶Adult: Initially 20 mg, administered within 2 hours before transplant surgery, followed by 20 mg after 4 days, dose to be administered after surgery, withhold second dose if severe hypersensitivity or graft loss occurs
PDF page 911
Off-label use in cardiac transplantation— increased risk of serious cardiac side-effects
PDF page 911
Immune system and malignant disease NICE decisions ▶Immunosuppressive therapy for kidney transplant in adults (October 2017) NICE TA481 Basiliximab, when used as part of an immunosuppressive regimen that includes a calcineurin inhibitor, is recommended as an initial option to prevent organ rejection in adults having a kidney transplant. The use of basiliximab with tacrolimus is outside the terms of the marketing authorisation. If this combination is prescribed, the prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their NHS clinician consider it appropriate to stop. www.nice.org.uk/guidance/TA481
PDF page 912
→Appendix 1: monoclonal antibodies
PDF page 911
Anaemia. capillary leak syndrome. constipation. cytokine release syndrome. diarrhoea. dyspnoea. electrolyte imbalance. headache. heart failure. hypercholesterolaemia. hypersensitivity. hypertension. hypotension. increased risk of infection. myocardial infarction. nausea. pain. peripheral oedema. post procedural wound complication. pulmonary oedema. respiratory disorders. skin reactions. sneezing. tachycardia. weight increased
PDF page 911
Adequate contraception must be used during treatment and for 16 weeks after last dose.
PDF page 911
Manufacturer advises avoid—no information available.
PDF page 912
Manufacturer advises avoid—no information available.
PDF page 912
For intravenous infusion (Simulect ®) give intermittently in Glucose 5% or Sodium chloride 0.9%; reconstitute 10 mg with 2.5 mL water for injections then dilute to at least 25 mL with infusion fluid; reconstitute 20 mg with 5 mL water for injections then dilute to at least 50 mL with infusion fluid; give over 20- 30 minutes.
PDF page 912
There can be variation in the licensing of different medicines containing the same drug. Powder and solvent for solution for injection ▶Simulect (Novartis Pharmaceuticals UK Ltd) Basiliximab 10 mg Simulect 10mg powder and solvent for solution for injection vials | 1 vial P £758.69 (Hospital only) Basiliximab 20 mg Simulect 20mg powder and solvent for solution for injection vials | 1 vial P £842.38 (Hospital only)
PDF page 912
Initially 20 mg, administered within 2 hours
First-line fragment. Read the complete Indications and Dose section above.
PDF page 911